Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting

Not Applicable

Completed

• Conditions: Post Operative Nausea and Vomiting
• Interventions: Dietary Supplement: administration of ondanstron and screening of genomic DNA

• Registration Number: NCT01657786
• Lead Sponsor: Yonsei University

Brief Summary

Postoperative nausea and vomiting (PONV) is a common and distressing complication in patients undergoing general anesthesia. However, although 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists have significantly reduced PONV, it is reported that over 35% of patients treated with ondansetron experience PONV. Though the cause of failure in ondansetron treatment is not clear, the investigators assumed that polymorphism in the 5-HT3 receptor gene would contribute to such inter-individual variation. In this study, the investigators examine whether the polymorphisms of 5-HT3 receptor gene affect the efficacy of ondansetron to prevent PONV in patients undergoing general anesthesia for laparoscopic surgery.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2008-05
• Primary Completion: 2009-02
• Study Completion: 2009-04
• Study First Submitted: 2012-07-28
• Status Verified: 2012-08
• Study First Submitted QC: 2012-08-03
• Last Update Submitted: 2012-08-03
• Study First Posted: 2012-08-06
• Last Update Posted: 2012-08-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 198

Inclusion Criteria

• Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia

Read More

Exclusion Criteria

• Patients with previous history of drug allergy,
• administration of antiemetic drugs within 24 hours,
• nausea/vomiting within 24 hours and liver or kidney disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ondansetron administration group	administration of ondanstron and screening of genomic DNA	-

Primary Outcome Measures

Name	Time	Method
The relationship between the incidence of PONV after ondansetron administration and genotypes in 5-HT3 receptor gene polymorphisms ((5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG)	at first 2 h and 2-24 h after surgery.	The incidence of PONV after ondansetron administration is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).

Trial Locations

Locations (1)

Associate Professor Department of Anesthesiology and Pain Medicine; 🇰🇷 Seoul, Korea, Republic of